Research and Markets (http://www.researchandmarkets.com/research/7hkjfn/pollen_allergy) has announced the addition of the "Pollen Allergy - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pollen Allergy and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- ALK-Abello A/S
- Allergopharma Joachim Ganzer KG
- Allergy Therapeutics Plc
- Anergis SA
- Biomay AG
- BioTech Tools s.a.
- Circassia Pharmaceuticals Plc
- HAL Allergy BV
- Immunomic Therapeutics, Inc.
- Japan Tobacco Inc.
- Laboratorios LETI S.L.
- REGiMMUNE Corporation
- Roxall Medizin GmbH
- Shionogi & Co., Ltd.
- Stallergenes S.A.
For more information visit http://www.researchandmarkets.com/research/7hkjfn/pollen_allergy
View source version on businesswire.com: http://www.businesswire.com/news/home/20151127005340/en/
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune
Disorders